PLGA microparticles entrapping chitosan-based nanoparticles for the ocular delivery of ranibizumab

Molecular Pharmaceutics

Volumn 13, Issue 9, 2016, Pages 2923-2940

  Elsaid, Naba ^a   Jackson, Timothy L ^b   Elsaid, Zeeneh ^c   Alqathama, Aljawharah ^c   Somavarapu, Satyanarayana ^c  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

age related macular degeneration; antiangiogenic; chitosan; hyaluronic acid; ranibizumab; sustained delivery

Indexed keywords

CHITOSAN NANOPARTICLE; POLYGLACTIN; RANIBIZUMAB; ACETYLCYSTEINE; CHITOSAN; CHITOSAN-N-ACETYLCYSTEINE CONJUGATE; HYALURONIC ACID; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYPHOSPHATE; TRIPHOSPHORIC ACID;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTON NUCLEAR MAGNETIC RESONANCE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; CELL LINE; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; MACULAR DEGENERATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; UMBILICAL VEIN ENDOTHELIAL CELL;

ACETYLCYSTEINE; CELL LINE; CELL MOVEMENT; CELL SURVIVAL; CHITOSAN; DRUG DELIVERY SYSTEMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYALURONIC ACID; LACTIC ACID; MACULAR DEGENERATION; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; POLYGLYCOLIC ACID; POLYPHOSPHATES; RANIBIZUMAB; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84986309156     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b00335     Document Type: Article

References (114)

1. Bunce, C.; Zekite, A.; Walton, S.; Rees, A.; Patel, P. J. Certifications for sight impairment due to age related macular degeneration in England Public Health 2015, 129, 138-42 10.1016/j.puhe.2014.12.018
2. NICE. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: NICE technology appraisal guidance [TA155]. 2008, [16/05/2016]. Available from: https://www.nice.org.uk/guidance/ta155/chapter/2-Clinical-need-and-practice.
3. Bakri, S. J.; Snyder, M. R.; Reid, J. M.; Pulido, J. S.; Ezzat, M. K.; Singh, R. J. Pharmacokinetics of intravitreal ranibizumab (Lucentis) Ophthalmology 2007, 114, 2179-82 10.1016/j.ophtha.2007.09.012
4. Sampat, K. M.; Garg, S. J. Complications of intravitreal injections Curr. Opin Ophthalmol. 2010, 21, 178-83 10.1097/ICU.0b013e328338679a
5. Grisanti, S.; Tura, A. [Qualitative differences between ranibizumab from original and ready to use syringes] Ophthalmologe 2010, 107, 1123-32 10.1007/s00347-010-2299-0
6. Kahook, M. Y.; Liu, L.; Ruzycki, P.; Mandava, N.; Carpenter, J. F.; Petrash, J. M.; Ammar, D. A. High-molecular-weight aggregates in repackaged bevacizumab Retina 2010, 30, 887-92 10.1097/IAE.0b013e3181d50cea
7. Ye, M.; Kim, S.; Park, K. Issues in long-term protein delivery using biodegradable microparticles J. Controlled Release 2010, 146, 241-60 10.1016/j.jconrel.2010.05.011
8. Shelke, N. B.; Kadam, R.; Tyagi, P.; Rao, V. R.; Kompella, U. B. Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases Drug Delivery Transl. Res. 2011, 1, 76-90 10.1007/s13346-010-0009-8
9. Yandrapu, S. K.; Upadhyay, A. K.; Petrash, J. M.; Kompella, U. B. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab Mol. Pharmaceutics 2013, 10, 4676-86 10.1021/mp400487f
10. van de Weert, M.; Hennink, W. E.; Jiskoot, W. Protein instability in poly(lactic-co-glycolic acid) microparticles Pharm. Res. 2000, 17, 1159-67 10.1023/A:1026498209874
11. Allison, S. D. Analysis of initial burst in PLGA microparticles Expert Opin. Drug Delivery 2008, 5, 615-28 10.1517/17425247.5.6.615
12. Hong, X.; Wei, L.; Ma, L.; Chen, Y.; Liu, Z.; Yuan, W. Novel preparation method for sustained-release PLGA microspheres using water-in-oil-in-hydrophilic-oil-in-water emulsion Int. J. Nanomed. 2013, 8, 2433-41 10.2147/IJN.S45186
13. Mao, S.; Xu, J.; Cai, C.; Germershaus, O.; Schaper, A.; Kissel, T. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres Int. J. Pharm. 2007, 334, 137-48 10.1016/j.ijpharm.2006.10.036
14. Hua, F. J.; Kim, G. E.; Lee, J. D.; Son, Y. K.; Lee, D. S. Macroporous poly(L-lactide) scaffold 1. Preparation of a macroporous scaffold by liquid - liquid phase separation of a PLLA - dioxane - water system J. Biomed. Mater. Res. 2002, 63, 161-7 10.1002/jbm.10121.abs
15. Harish Prashanth, K. V.; Tharanathan, R. N. Depolymerized products of chitosan as potent inhibitors of tumor-induced angiogenesis Biochim. Biophys. Acta, Gen. Subj. 2005, 1722, 22-9 10.1016/j.bbagen.2004.11.009
16. Xu, Y.; Wen, Z.; Xu, Z. Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism Anticancer Res. 2009, 29, 5103-9
17. Okamoto, H.; Umeda, S.; Obazawa, M.; Minami, M.; Noda, T.; Mizota, A.; Honda, M.; Tanaka, M.; Koyama, R.; Takagi, I.; Sakamoto, Y.; Saito, Y.; Miyake, Y.; Iwata, T. Complement factor H polymorphisms in Japanese population with age-related macular degeneration Mol. Vis. 2006, 12, 156-8
18. Kim, M. M.; Kim, S. K. Chitooligosaccharides inhibit activation and expression of matrix metalloproteinase-2 in human dermal fibroblasts FEBS Lett. 2006, 580, 2661-6 10.1016/j.febslet.2006.04.015
19. Liu, H.-t.; Huang, P.; Ma, P.; Liu, Q.-s.; Yu, C.; Du, Y.-g. Chitosan oligosaccharides suppress LPS-induced IL-8 expression in human umbilical vein endothelial cells through blockade of p38 and Akt protein kinases Acta Pharmacol. Sin. 2011, 32, 478-86 10.1038/aps.2011.10
20. Kievit, F. M.; Cooper, A.; Jana, S.; Leung, M. C.; Wang, K.; Edmondson, D.; Wood, D.; Lee, J. S.; Ellenbogen, R. G.; Zhang, M. Aligned chitosan-polycaprolactone polyblend nanofibers promote the migration of glioblastoma cells Adv. Healthcare Mater. 2013, 2, 1651-9 10.1002/adhm.201300092
21. McBane, J. E.; Vulesevic, B.; Padavan, D. T.; McEwan, K. A.; Korbutt, G. S.; Suuronen, E. J. Evaluation of a collagen-chitosan hydrogel for potential use as a pro-angiogenic site for islet transplantation PLoS One 2013, 8, e77538 10.1371/journal.pone.0077538
22. Miklas, J. W.; Dallabrida, S. M.; Reis, L. A.; Ismail, N.; Rupnick, M.; Radisic, M. QHREDGS enhances tube formation, metabolism and survival of endothelial cells in collagen-chitosan hydrogels PLoS One 2013, 8, e72956 10.1371/journal.pone.0072956
23. Kogan, G.; Soltes, L.; Stern, R.; Gemeiner, P. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications Biotechnol. Lett. 2007, 29, 17-25 10.1007/s10529-006-9219-z
24. Oh, E. J.; Park, K.; Kim, K. S.; Kim, J.; Yang, J. A.; Kong, J. H.; Lee, M. Y.; Hoffman, A. S.; Hahn, S. K. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives J. Controlled Release 2010, 141, 2-12 10.1016/j.jconrel.2009.09.010
25. Rooney, P.; Kumar, S. Inverse relationship between hyaluronan and collagens in development and angiogenesis Differentiation 1993, 54, 1-9 10.1111/j.1432-0436.1993.tb00653.x
26. Nasti, A.; Zaki, N. M.; de Leonardis, P.; Ungphaiboon, S.; Sansongsak, P.; Rimoli, M. G.; Tirelli, N. Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimization of the preparative process and preliminary biological evaluation Pharm. Res. 2009, 26, 1918-30 10.1007/s11095-009-9908-0
27. Bernkop-Schnurch, A.; Hornof, M.; Guggi, D. Thiolated chitosans Eur. J. Pharm. Biopharm. 2004, 57, 9-17 10.1016/S0939-6411(03)00147-4
28. EMEA; European Medicines Evaluation Agency (2007). Scientific discussion. Available URL http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000715/WC500043550.pdf [Cited: 13.11.14].
29. Hoeben, A.; Landuyt, B.; Highley, M. S.; Wildiers, H.; Van Oosterom, A. T.; De Bruijn, E. A. Vascular endothelial growth factor and angiogenesis Pharmacol Rev. 2004, 56, 549-80 10.1124/pr.56.4.3
30. Aluigi, M. G.; De Flora, S.; D'Agostini, F.; Albini, A.; Fassina, G. Antiapoptotic and antigenotoxic effects of N-acetylcysteine in human cells of endothelial origin Anticancer Res. 2000, 20, 3183-7
31. de Oliveira Dias, J. R.; Rodrigues, E. B.; Maia, M.; Magalhaes, O., Jr.; Penha, F. M.; Farah, M. E. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy Br. J. Ophthalmol. 2011, 95, 1631-7 10.1136/bjo.2010.186361
32. Calvo, P.; Vila-Jato, J. L.; Alonso, M.a.J. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers Int. J. Pharm. 1997, 153, 41-50 10.1016/S0378-5173(97)00083-5
33. Schmitz, T.; Grabovac, V.; Palmberger, T. F.; Hoffer, M. H.; Bernkop-Schnurch, A. Synthesis and characterization of a chitosan-N-acetyl cysteine conjugate Int. J. Pharm. 2008, 347, 79-85 10.1016/j.ijpharm.2007.06.040
34. Ghasemian, E.; Vatanara, A.; Rouholamini Najafabadi, A.; Rouini, M. R.; Gilani, K.; Darabi, M. Preparation, characterization and optimization of sildenafil citrate loaded PLGA nanoparticles by statistical factorial design Daru, J. Pharm. Sci. 2013, 21, 68 10.1186/2008-2231-21-68
35. Li, F.; Hurley, B.; Liu, Y.; Leonard, B.; Griffith, M. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration Open Ophthalmol. J. 2012, 6, 54-8 10.2174/1874364101206010054
36. Chereddy, K. K.; Her, C. H.; Comune, M.; Moia, C.; Lopes, A.; Porporato, P. E.; Vanacker, J.; Lam, M. C.; Steinstraesser, L.; Sonveaux, P.; Zhu, H.; Ferreira, L. S.; Vandermeulen, G.; Preat, V. PLGA nanoparticles loaded with host defense peptide LL37 promote wound healing J. Controlled Release 2014, 194, 138-47 10.1016/j.jconrel.2014.08.016
37. D'Souza, S. S.; DeLuca, P. P. Methods to assess in vitro drug release from injectable polymeric particulate systems Pharm. Res. 2006, 23, 460-74 10.1007/s11095-005-9397-8
38. Liu, F.; Merchant, H. A.; Kulkarni, R. P.; Alkademi, M.; Basit, A. W. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products Eur. J. Pharm. Biopharm. 2011, 78, 151-7 10.1016/j.ejpb.2011.01.001
39. Kaja, S.; Hilgenberg, J. D.; Everett, E.; Olitsky, S. E.; Gossage, J.; Koulen, P. Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies Hum. Antibodies 2011, 20, 95-101 10.3233/HAB-2011-0244
40. Folkman, J.; Klagsbrun, M. Angiogenic factors Science 1987, 235, 442-7 10.1126/science.2432664
41. Hotchkiss, K. A.; Ashton, A. W.; Mahmood, R.; Russell, R. G.; Sparano, J. A.; Schwartz, E. L. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center Mol. Cancer Ther. 2002, 1, 1191-200
42. Hrynyk, M.; Martins-Green, M.; Barron, A. E.; Neufeld, R. J. Sustained prolonged topical delivery of bioactive human insulin for potential treatment of cutaneous wounds Int. J. Pharm. 2010, 398, 146-54 10.1016/j.ijpharm.2010.07.052
43. Iriyama, A.; Fujiki, R.; Inoue, Y.; Takahashi, H.; Tamaki, Y.; Takezawa, S.; Takeyama, K.; Jang, W. D.; Kato, S.; Yanagi, Y. A2E, a pigment of the lipofuscin of retinal pigment epithelial cells, is an endogenous ligand for retinoic acid receptor J. Biol. Chem. 2008, 283, 11947-53 10.1074/jbc.M708989200
44. Yu, W.; Bai, Y.; Han, N.; Wang, F.; Zhao, M.; Huang, L.; Li, X. Inhibition of pathological retinal neovascularization by semaphorin 3A Mol. Vis. 2013, 19, 1397-405
45. Wang, X.; Zheng, C.; Wu, Z.; Teng, D.; Zhang, X.; Wang, Z.; Li, C. Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin J. Biomed. Mater. Res., Part B 2009, 88B, 150-61 10.1002/jbm.b.31161
46. Ponedel'kina, I. Y.; Odinokov, V. N.; Saitgalina, E. A.; Lukina, E. S.; Dzhemilev, U. M. Conjugation of 3′-azido-3′-deoxythymidine with heparin Dokl. Chem. 2008, 419, 95-7 10.1134/S0012500808040046
47. Lee, Y. S.; Johnson, P. J.; Robbins, P. T.; Bridson, R. H. Production of nanoparticles-in-microparticles by a double emulsion method: A comprehensive study Eur. J. Pharm. Biopharm. 2013, 83, 168-73 10.1016/j.ejpb.2012.10.016
48. Wadhwa, S.; Paliwal, R.; Paliwal, S. R.; Vyas, S. P. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation Journal of Drug Targeting. 2010, 18, 292-302 10.3109/10611860903450023
49. Luangtana-anan, M.; Opanasopit, P.; Ngawhirunpat, T.; Nunthanid, J.; Sriamornsak, P.; Limmatvapirat, S.; Lim, L. Y. Effect of chitosan salts and molecular weight on a nanoparticulate carrier for therapeutic protein Pharm. Dev. Technol. 2005, 10, 189-96 10.1081/PDT-200054388
50. Talaei, F.; Azizi, E.; Dinarvand, R.; Atyabi, F. Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells Int. J. Nanomed. 2011, 6, 1963-75 10.2147/IJN.S22731
51. Hombach, J.; Hoyer, H.; Bernkop-Schnurch, A. Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system Eur. J. Pharm. Sci. 2008, 33, 1-8 10.1016/j.ejps.2007.09.001
52. Parajo, Y.; D'Angelo, I.; Welle, A.; Garcia-Fuentes, M.; Alonso, M. J. Hyaluronic acid/Chitosan nanoparticles as delivery vehicles for VEGF and PDGF-BB Drug Delivery 2010, 17, 596-604 10.3109/10717544.2010.509357
53. de la Fuente, M.; Seijo, B.; Alonso, M. J. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy Invest. Ophthalmol. Visual Sci. 2008, 49, 2016-24 10.1167/iovs.07-1077
54. Wen, H.; Hao, J.; Li, S. K. Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab J. Pharm. Sci. 2013, 102, 892-903 10.1002/jps.23387
55. Janes, K. A.; Calvo, P.; Alonso, M. J. Polysaccharide colloidal particles as delivery systems for macromolecules Adv. Drug Delivery Rev. 2001, 47, 83-97 10.1016/S0169-409X(00)00123-X
56. Pan, Y.; Li, Y. J.; Zhao, H. Y.; Zheng, J. M.; Xu, H.; Wei, G.; Hao, J. S.; Cui, F. D. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo Int. J. Pharm. 2002, 249, 139-47 10.1016/S0378-5173(02)00486-6
57. Qi, L.; Xu, Z.; Jiang, X.; Hu, C.; Zou, X. Preparation and antibacterial activity of chitosan nanoparticles Carbohydr. Res. 2004, 339, 2693-700 10.1016/j.carres.2004.09.007
58. Aktaş, Y.; Andrieux, K.; Alonso, M. J.; Calvo, P.; Gürsoy, R. N.; Couvreur, P.; Çapan, Y. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor Int. J. Pharm. 2005, 298, 378-83 10.1016/j.ijpharm.2005.03.027
59. Ferlay, J.; Parkin, D. M.; Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008 Eur. J. Cancer 2010, 46, 765-81 10.1016/j.ejca.2009.12.014
60. Mohammadpour Dounighi, N.; Eskandari, R.; Avadi, M.; Zolfagharian, H.; Mir Mohammad Sadeghi, A.; Rezayat, M. Preparation and in vitro characterization of chitosan nanoparticles containing Mesobuthus eupeus scorpion venom as an antigen delivery system J. Venomous Anim. Toxins Incl. Trop. Dis. 2012, 18, 44-52 10.1590/S1678-91992012000100006
61. Silverstein, R. M.; Bassler, G. C.; Morrill, T. C. Spectrometric Identification of Organic Compounds; John Wiley and Sons: New York, 1981.
62. Mi, F.-L.; Shyu, S.-S.; Wong, T.-B.; Jang, S.-F.; Lee, S.-T.; Lu, K.-T. Chitosan-polyelectrolyte complexation for the preparation of gel beads and controlled release of anticancer drug. II. Effect of pH-dependent ionic crosslinking or interpolymer complex using tripolyphosphate or polyphosphate as reagent J. Appl. Polym. Sci. 1999, 74, 1093-107 10.1002/(SICI)1097-4628(19991031)74:5<1093::AID-APP6>3.0.CO;2-C
63. Yang, M.-H.; Jong, S.-B.; Lu, C.-Y.; Lin, Y.-F.; Chiang, P.-W.; Tyan, Y.-C.; Chung, T.-W. Assessing the responses of cellular proteins induced by hyaluronic acid-modified surfaces utilizing a mass spectrometry-based profiling system: Over-expression of CD36, CD44, CDK9, and PP2A Analyst 2012, 137, 4921-33 10.1039/c2an35368g
64. Oliveira, R. C.; Messias, A.; Siqueira, R. C.; Bonini-Filho, M. A.; Haddad, A.; Damico, F. M.; Maia-Filho, A.; Crispim, P. T.; Saliba, J. B.; Ribeiro, J. A.; Scott, I. U.; Cunha-Jr, A. S.; Jorge, R. Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes Curr. Eye Res. 2012, 37, 55-61 10.3109/02713683.2011.593722
65. Murthy, R.; Khattar, H.; Singh, S. Formulation and characterization of nano lipid carrier dry powder inhaler containing ciprofloxacin hydrochloride and N-acetyl cysteine Int. J. Drug Delivery 2012, 4, 316-25
66. Hsieh, D. S.; Rhine, W. D.; Langer, R. Zero-order controlled-release polymer matrices for micro- and macromolecules J. Pharm. Sci. 1983, 72, 17-22 10.1002/jps.2600720105
67. Chandy, T.; Das, G. S.; Rao, G. H. 5-Fluorouracil-loaded chitosan coated polylactic acid microspheres as biodegradable drug carriers for cerebral tumours J. Microencapsulation 2000, 17, 625-38 10.1080/026520400417676
68. Dhawan, S.; Singla, A. K. Nifedipine loaded chitosan microspheres prepared by emulsification phase-separation Biotech. Histochem. 2003, 78, 243-54 10.1080/1052090310001602396
69. Liu, G.; Miao, X.; Fan, W.; Crawford, R. W.; Xiao, Y. Porous PLGA microspheres effectively loaded with BSA protein by electrospraying combined with phase separation in liquid nitrogen J. Biomimetics, Biomater., Tissue Eng. 2010, 6, 1-18 10.4028/www.scientific.net/JBBTE.6.1
70. Lian, H.; Zhang, T.; Sun, J.; Pu, X.; Tang, Y.; Zhang, Y.; He, Z. Enhanced paracellular and transcellular paclitaxel permeation by chitosan-vitamin E succinate-N-acetyl-l-cysteine copolymer on Caco-2 cell monolayer J. Nanopart. Res. 2014, 16, 1-16 10.1007/s11051-014-2355-9
71. Pieper, G. M.; Siebeneich, W. Oral administration of the antioxidant, N-acetylcysteine, abrogates diabetes-induced endothelial dysfunction J. Cardiovasc. Pharmacol. 1998, 32, 101-5 10.1097/00005344-199807000-00016
72. Sturesson, C.; Carlfors, J. Incorporation of protein in PLG-microspheres with retention of bioactivity J. Controlled Release 2000, 67, 171-8 10.1016/S0168-3659(00)00205-4
73. Ramchandani, M.; Robinson, D. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants J. Controlled Release 1998, 54, 167-75 10.1016/S0168-3659(97)00113-2
74. Amann, L. C.; Gandal, M. J.; Lin, R.; Liang, Y.; Siegel, S. J. In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia Pharm. Res. 2010, 27, 1730-7 10.1007/s11095-010-0152-4
75. Murugeshu, A.; Astete, C.; Leonardi, C.; Morgan, T.; Sabliov, C. M. Chitosan/PLGA particles for controlled release of alpha-tocopherol in the GI tract via oral administration Nanomedicine (London, U. K.) 2011, 6, 1513-28 10.2217/nnm.11.44
76. Jain, G. K.; Pathan, S. A.; Akhter, S.; Ahmad, N.; Jain, N.; Talegaonkar, S.; Khar, R. K.; Ahmad, F. J. Mechanistic study of hydrolytic erosion and drug release behaviour of PLGA nanoparticles: Influence of chitosan Polym. Degrad. Stab. 2010, 95, 2360-6 10.1016/j.polymdegradstab.2010.08.015
77. Wang, Y.; Li, P.; Kong, L. Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery AAPS PharmSciTech 2013, 14, 585-92 10.1208/s12249-013-9943-3
78. Lee, E. S.; Kwon, M. J.; Lee, H.; Na, K.; Kim, J. J. In vitro study of lysozyme in poly(lactide-co-glycolide) microspheres with sucrose acetate isobutyrate Eur. J. Pharm. Sci. 2006, 29, 435-41 10.1016/j.ejps.2006.08.005
79. Bouissou, C.; Rouse, J. J.; Price, R.; van der Walle, C. F. The influence of surfactant on PLGA microsphere glass transition and water sorption: remodeling the surface morphology to attenuate the burst release Pharm. Res. 2006, 23, 1295-305 10.1007/s11095-006-0180-2
80. Klettner, A.; Roider, J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways Invest. Ophthalmol. Visual Sci. 2008, 49, 4523-7 10.1167/iovs.08-2055
81. Harde, H.; Agrawal, A. K.; Jain, S. Tetanus toxoids loaded glucomannosylated chitosan based nanohoming vaccine adjuvant with improved oral stability and immunostimulatory response Pharm. Res. 2015, 32, 122-34 10.1007/s11095-014-1449-5
82. Anderson, J. M.; Shive, M. S. Biodegradation and biocompatibility of PLA and PLGA microspheres Adv. Drug Delivery Rev. 1997, 28, 5-24 10.1016/S0169-409X(97)00048-3
83. Semete, B.; Booysen, L.; Lemmer, Y.; Kalombo, L.; Katata, L.; Verschoor, J.; Swai, H. S. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems Nanomedicine 2010, 6, 662-71 10.1016/j.nano.2010.02.002
84. Souza, M. C.; Fialho, S. L.; Souza, P. A.; Fulgencio, G. O.; Da Silva, G. R.; Silva-Cunha, A. Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity Curr. Eye Res. 2014, 39, 99-102 10.3109/02713683.2013.819927
85. Yang, H.; Yang, L.; Wang, L.; Diao, Y. Preparation of Aptamer-Nanomicrocapsule Using Nanoprecipitation Method Int. J. Adv. Comput. Technol. 2013, 5, 585 10.4156/ijact.vol5.issue8.66
86. Grenha, A.; Grainger, C. I.; Dailey, L. A.; Seijo, B.; Martin, G. P.; Remuñán-López, C.; Forbes, B. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro Eur. J. Pharm. Sci. 2007, 31, 73-84 10.1016/j.ejps.2007.02.008
87. Manca, M.-L.; Mourtas, S.; Dracopoulos, V.; Fadda, A. M.; Antimisiaris, S. G. PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery?: A comparative study of particle stability during nebulization Colloids Surf., B 2008, 62, 220-31 10.1016/j.colsurfb.2007.10.005
88. Zhu, X.; Su, M.; Tang, S.; Wang, L.; Liang, X.; Meng, F.; Hong, Y.; Xu, Z. Synthesis of thiolated chitosan and preparation nanoparticles with sodium alginate for ocular drug delivery Mol. Vis. 2012, 18, 1973-82
89. Wang, Q.; Liu, P.; Liu, P.; Gong, T.; Li, S.; Duan, Y.; Zhang, Z. Preparation, blood coagulation and cell compatibility evaluation of chitosan-graft-polylactide copolymers Biomed. Mater. 2014, 9, 015007 10.1088/1748-6041/9/1/015007
90. Kageyama, T.; Kakegawa, T.; Osaki, T.; Enomoto, J.; Ito, T.; Nittami, T.; Fukuda, J. Rapid engineering of endothelial cell-lined vascular-like structures in in situ crosslinkable hydrogels Biofabrication 2014, 6, 025006 10.1088/1758-5082/6/2/025006
91. Giebel, S. J.; Menicucci, G.; McGuire, P. G.; Das, A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier Lab. Invest. 2005, 85, 597-607 10.1038/labinvest.3700251
92. Dunn, K. C.; Aotaki-Keen, A. E.; Putkey, F. R.; Hjelmeland, L. M. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties Exp. Eye Res. 1996, 62, 155-69 10.1006/exer.1996.0020
93. Hornof, M.; Toropainen, E.; Urtti, A. Cell culture models of the ocular barriers Eur. J. Pharm. Biopharm. 2005, 60, 207-25 10.1016/j.ejpb.2005.01.009
94. Feng, L.; Kienitz, B. A.; Matsumoto, C.; Bruce, J.; Sisti, M.; Duong, H.; Pile-Spellman, J. Feasibility of using hyperosmolar mannitol as a liquid tumor embolization agent AJNR Am. J. Neuroradiol. 2005, 26, 1405-12
95. van der Meer, A. D.; Vermeul, K.; Poot, A. A.; Feijen, J.; Vermes, I. A microfluidic wound-healing assay for quantifying endothelial cell migration AJP: Heart Circ. Physiol. 2010, 298, H719-H725 10.1152/ajpheart.00933.2009
96. Schipper, N. G.; Olsson, S.; Hoogstraate, J. A.; deBoer, A. G.; Varum, K. M.; Artursson, P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement Pharm. Res. 1997, 14, 923-9 10.1023/A:1012160102740
97. Bozhokina, E.; Vakhromova, E.; Gamaley, I.; Khaitlina, S. N-acetylcysteine increases susceptibility of HeLa cells to bacterial invasion J. Cell. Biochem. 2013, 114, 1568-74 10.1002/jcb.24498
98. Folkman, J. Tumor angiogenesis Adv. Cancer Res. 1985, 43, 175-203 10.1016/S0065-230X(08)60946-X
99. Ferrara, N.; Damico, L.; Shams, N.; Lowman, H.; Kim, R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 2006, 26, 859-70 10.1097/01.iae.0000242842.14624.e7
100. Costa, R.; Carneiro, A.; Rocha, A.; Pirraco, A.; Falcao, M.; Vasques, L.; Soares, R. Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study J. Cell. Biochem. 2009, 108, 1410-7 10.1002/jcb.22378
101. Carrasquillo, K. G.; Ricker, J. A.; Rigas, I. K.; Miller, J. W.; Gragoudas, E. S.; Adamis, A. P. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres Invest. Ophthalmol. Visual Sci. 2003, 44, 290-9 10.1167/iovs.01-1156
102. Pan, C. K.; Durairaj, C.; Kompella, U. B.; Agwu, O.; Oliver, S. C.; Quiroz-Mercado, H.; Mandava, N.; Olson, J. L. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model J. Ocul. Pharmacol. Ther. 2011, 27, 219-24 10.1089/jop.2010.0158
103. Lu, W.; Park, T. G. Protein release from poly(lactic-co-glycolic acid) microspheres: protein stability problems PDA J. Pharm. Sci. Technol. 1995, 49, 13-9
104. Crotts, G.; Park, T. G. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues J. Microencapsulation 1998, 15, 699-713 10.3109/02652049809008253
105. Lin, M. T.; Yen, M. L.; Lin, C. Y.; Kuo, M. L. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation Mol. Pharmacol. 2003, 64, 1029-36 10.1124/mol.64.5.1029
106. Okamoto, Y.; Watanabe, M.; Miyatake, K.; Morimoto, M.; Shigemasa, Y.; Minami, S. Effects of chitin/chitosan and their oligomers/monomers on migrations of fibroblasts and vascular endothelium Biomaterials 2002, 23, 1975-9 10.1016/S0142-9612(01)00324-6
107. Chen, Y. L.; Wang, C. Y.; Yang, F. Y.; Wang, B. S.; Chen, J. Y.; Lin, L. T.; Leu, J. D.; Chiu, S. J.; Chen, F. D.; Lee, Y. J.; Chen, W. R. Synergistic effects of glycated chitosan with high-intensity focused ultrasound on suppression of metastases in a syngeneic breast tumor model Cell Death Dis. 2014, 5, e1178 10.1038/cddis.2014.159
108. Arnaoutova, I.; Kleinman, H. K. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract Nat. Protoc. 2010, 5, 628-35 10.1038/nprot.2010.6
109. Jin, S. G.; Jeong, Y. I.; Jung, S.; Ryu, H. H.; Jin, Y. H.; Kim, I. Y. The effect of hyaluronic Acid on the invasiveness of malignant glioma cells: comparison of invasion potential at hyaluronic Acid hydrogel and Matrigel J. Korean Neurosurg. Soc. 2009, 46, 472-8 10.3340/jkns.2009.46.5.472
110. Ito, T.; Williams, J. D.; Al-Assaf, S.; Phillips, G. O.; Phillips, A. O. Hyaluronan and proximal tubular cell migration Kidney Int. 2004, 65, 823-33 10.1111/j.1523-1755.2004.00457.x
111. Wang, Z.; Perez, M.; Caja, S.; Melino, G.; Johnson, T. S.; Lindfors, K.; Griffin, M. A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis Cell Death Dis. 2013, 4, e808 10.1038/cddis.2013.318
112. Carneiro, A.; Falcao, M.; Pirraco, A.; Milheiro-Oliveira, P.; Falcao-Reis, F.; Soares, R. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells Exp. Eye Res. 2009, 88, 522-7 10.1016/j.exer.2008.11.011
113. Medina, R. J.; O'Neill, C. L.; Devine, A. B.; Gardiner, T. A.; Stitt, A. W. The Pleiotropic Effects of Simvastatin on Retinal Microvascular Endothelium Has Important Implications for Ischaemic Retinopathies PLoS One 2008, 3, e2584 10.1371/journal.pone.0002584
114. Feinberg, R. N.; Beebe, D. C. Hyaluronate in vasculogenesis Science 1983, 220, 1177-9 10.1126/science.6857242